A phase I clinical trial included 40 patients with HLA-A0201+ CEA+ advanced CRC who were randomly treated with AEX (ascites-derived exosomes) or AEX plus GM-CSF, and both methods were safe and tolerable. This evidence concerns the gene CEACAM5 and colorectal carcinoma.